Table 2 Correlation between FAK expression and clinicopathological characteristics in primary tumors
Characteristic | FAK ≤ 4 low | FAK > 4 high | Total number | P-value |
|---|---|---|---|---|
Number of cases | 143 (73%) | 53 (27%) | 196 | |
Age (median) | 57 | 51 | 56 | 0.033 |
Positive Lymph nodes (median) | 3.0 | 5.0 | 4.0 | 0.062 |
Histological grade | ||||
Grade I (well differentiated) | 7 (5.2%) | 7 | 0.143 | |
Grade II (moderately differentiated) | 23 (17.0%) | 13 (24.5%) | 36 | |
Grade III (poorly differentiated) | 105 (77.8%) | 40 (75.5%) | 145 | |
Stage | ||||
Stage IIA | 48 (33.8%) | 10 (18.9%) | 58 | 0.124 |
Stage IIB | 52 (36.6%) | 23 (43.4%) | 75 | |
Stage IIIA | 12 (8.5%) | 11 (20.8%) | 23 | |
Stage IIIB | 20 (14.1%) | 6 (11.3%) | 26 | |
Stage IIIC | 3 (2.1%) | 1 (1.9%) | 4 | |
Stage IV | 7 (4.9%) | 2 (3.8%) | 9 | |
Estrogen receptor (ER) | ||||
Positive | 115 (81.6%) | 40 (75.5%) | 155 | 0.346 |
Negative | 26 (18.4%) | 13 (24.5%) | 39 | |
Progesterone receptor (PR) | ||||
Positive | 86 (61.0%) | 26 (49.1%) | 112 | 0.134 |
Negative | 111 (79.3%) | 41 (77.4%) | 152 | |
HER-2 | ||||
Positive | 29 (20.7%) | 12 (22.6%) | 41 | 0.770 |
Negative | 111 (79.3%) | 41 (77.4%) | 152 | |
Triple negative status | ||||
No | 126 (90.6%) | 42 (79.2%) | 168 | 0.033 |
Lymphovascular invasion (LVI) | ||||
No | 75 (56.8%) | 16 (30.8%) | 91 | 0.001 |
Yes | 57 (43.2%) | 36 (54.4%) | 93 |